Regeneron Pharmaceuticals is planning to acquire CMPI stock for $10.50 per share. That represents a massive 335.7% premium over the stock’s closing price on Monday. It’s also worth mentioning that the offer from REGN is in cash.
The deal between the two values Checkmate Pharmaceuticals at $250 million. Regeneron Pharmaceuticals’ interest in CMPI is due to its lead investigational candidate vidutolimod. This is a treatment designed to use the immune system to treat various cancers.
Art Krieg, M.D., founder and CSO of Checkmate Pharmaceuticals, said the following about today’s news.
“We believe that the data we have generated with vidutolimod positions Checkmate at the forefront of the innate immune activator field. It is our hope that Regeneron’s resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy.”
Checkmate Pharmaceuticals and Regeneron Pharmaceuticals are expecting the acquisition deal to close in mid-2022. The deal will be completed through a tender offer made by a subsidiary of the latter that will merge with CMPI.
CMPI stock is experiencing heavy trading following today’s merger news. As of this writing, more than 3 million shares of the stock have changed hands. That’s a major increase over its daily average trading volume of only about 13,000 shares.
CMPI stock is up 329% as of Tuesday afternoon.
Investors looking for more stock market news today are in luck!
InvestorPlace has you covered with all the latest stock happenings for Tuesday! A few examples include why American Campus Communities (NYSE:ACC) stock is rising, what has hydrogen stocks on the move today, as well as a new twist in the Elon Musk Twitter (NYSE:TWTR) story. You can find out all about these topics at the following links!
More Stock Market News for Tuesday
- Why Is American Campus Communities (ACC) Stock Up Today?
- Hydrogen Stocks News: Why Are PLUG, FCEL, BE Stocks Up Today?
- Apollo Global May Back Elon Musk. What Does That Mean for TWTR Stock?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed